- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03418428
Intestinal Microbiome After Gastrectomy (DiGMA)
Surgical Gastric Cancer Treatment: Influence on Intestinal Microbiome
The gastric barrier plays a major role in the maintanance of the distal intestinal microbiome composition. It has been shown before that the use of gastric acid suppression medication, such as proton pump inhibitors, are associated with distinctive alterations of the intestinal microbiome. Foremost, the invasion of predominantly oral bacteria, like Veillonella and Streptococcus species, were a resurring finding in previous reports.
Gastric cancer treatment includes the total or subtotal resection of the stomach which can influence the gastric acid production. However, the influence by alterations in gastric milieu after this treatment on the composition of the intestinal microbiome is not well studied.
Therefore, the intestinal microbiome of patients after total or subtotal gastrectomy and its influence on intestinal inflammation and gut permeability will be studied.
연구 개요
상태
정황
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Vilnius, 리투아니아
- National Cancer Institute
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- age 18 years and above
- history of radical removal of gastric cancer (Test group and Control group 1) or PPI (Control group 3)
- informed consent
Exclusion Criteria:
- chemotherapy or radiotherapy 12 months prior to inclusion
- gastric stump cancer
- usage of antibiotics, pro- pre or synbiotics, H2-blocker 1 month prior to inclusion
- PPI use (except for Control group 3) 1 month prior to inclusion
- history of radical removal of gastric cancer (Control group 2-3)
- history of gastrointestinal tract resections (other than gastric)
- recurrence of gastric cancer
- current non-gastric malignancies
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
---|
Test group
Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
|
Control group 1
Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
|
Control group 2
In-house relatives of Test group and Control group 1 participants
|
Control group 3
Patients with long-term history of proton pump inhibitor usage
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Intestinal microbiome composition
기간: 5 years after surgery
|
Significant differences in the beta-diversity of the intestinal microbiome between Test group and Control groups
|
5 years after surgery
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Intestinal microbiome composition (II)
기간: 5 years after surgery
|
Significant differences in the alpha-diversity of the intestinal microbiome between Test group and Control groups
|
5 years after surgery
|
Fecal calprotectin
기간: 5 years after surgery
|
Significant differences in intestinal inflammation measured by fecal calprotectin between Test group and Control groups
|
5 years after surgery
|
Fecal zonulin
기간: 5 years after surgery
|
Significant differences in intestinal permeability measured by fecal zonulin between Test group and Control groups
|
5 years after surgery
|
Serum LPS
기간: 5 years after surgery
|
Significant differences in serum LPS between Test group and Control groups
|
5 years after surgery
|
Serum sCD14
기간: 5 years after surgery
|
Significant differences in serum sCD14 between Test group and Control groups
|
5 years after surgery
|
Serum LBP
기간: 5 years after surgery
|
Significant differences in serum LBP between Test group and Control groups
|
5 years after surgery
|
Serum sCD163
기간: 5 years after surgery
|
Significant differences in serum sCD163 between Test group and Control groups
|
5 years after surgery
|
Serum sMR
기간: 5 years after surgery
|
Significant differences in serum sMR between Test group and Control groups
|
5 years after surgery
|
Serum CRP
기간: 5 years after surgery
|
Significant differences in serum CRP between Test group and Control groups
|
5 years after surgery
|
Serum DAO
기간: 5 years after surgery
|
Significant differences in serum DAO between Test group and Control groups
|
5 years after surgery
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
위암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
-
Jonsson Comprehensive Cancer Center종료됨생화학적으로 재발하는 전립선암 | 전이성 전립선암 | 뼈의 전이성 악성 신생물 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국